Anthropic, the parent company of Claude, has confidentially filed IPO documents (an S-1) with the SEC. OpenAI followed a week later on the same track. This is not a public filing — the share count, price, valuation, listing date, and financials are all out of view.

This piece follows the beginner’s question order: what a confidential filing is → confirmed numbers → IPO preparation status → how to participate by region. To be clear: this helps you understand the event, not decide whether to buy. To get to know the company first, read What Is Anthropic?.

Sources fall into three kinds: [filing] = Anthropic official or SEC documents, [media] = Reuters, Bloomberg, and similar named reports, [calculation] = derived from published figures.

What a Confidential Filing Is

  • Company: Anthropic, PBC (a public benefit corporation)
  • Action: confidentially filed a draft S-1 with the SEC [filing]
  • Status: draft filed, but no public formal S-1 yet. Share count, price, valuation, ticker, and listing date are all undetermined [filing]
  • The company’s words: this gives it “the option to list following the completion of the SEC’s review” [filing]

This is the start of the process, not the end. Citing Rule 135, the company states this filing is not an offer to sell securities [filing].

Why you can’t find its financials: A confidential filing is designed not to be public. The U.S. JOBS Act lets a company have the SEC review its documents privately, keeping financials hidden and retaining the option to walk away. The documents must go public at least 15 days before the formal roadshow. So Anthropic’s real financials won’t appear until it decides to move forward — every “financial figure” you see now comes from other sources, not this S-1.

Anthropic IPO process timeline: confidential draft S-1 (you are here) → SEC review → public formal S-1 → roadshow → pricing → listing
The standard IPO process. Anthropic is at step 1 (confidential filing); financials are disclosed at step 3; retail investors can buy at step 6.

Known vs. Unknown

Known ✅Unknown ❓
Confidential draft S-1 filed [filing]Full financials (GAAP revenue, P&L)
Private-round valuation ~US$965 billion [filing]IPO share count and price
Self-reported ARR ~US$47 billion [filing]IPO valuation (market transaction price)
Reported ARR now above US$65 billion [media]Ticker, listing exchange
Reported IPO valuation may exceed US$2 trillion [media]Listing date (reportedly October at earliest; not confirmed)
Underwriting led by Morgan Stanley, Goldman Sachs [media]
Former Fed Chair Bernanke joins LTBT [filing]
OpenAI also on the confidential filing track [filing]

Everything confirmed is a private-stage number; the media-reported figures are higher, but neither equals the price you’ll buy at in the stock market.

Revenue and Valuation

No IPO financials yet, but private-round and self-reported numbers give an outline:

  • How it makes money: enterprises and developers paying for Claude, driven especially by coding (Claude Code) and AI agent workflows [media].
  • Most recent round: Series H raised US$65 billion at about US$965 billion post-money [filing], surpassing OpenAI’s US$852 billion for the first time [calculation].
  • Revenue (ARR): the company reported ARR of about US$47 billion in May [filing]. Reuters reports this topped US$65 billion by late July [media], up nearly 40% in two months. Separately, Anthropic’s internal forecast for 2028 revenue is reportedly US$190–200 billion [media]. ARR is an annualized estimate, not full-year actual revenue.
  • Investors: Amazon (largest cumulative investor), Google, Fidelity, GIC, Temasek, plus Samsung, SK hynix, and Micron as new HBM memory partners in Series H [filing].
Latest private-round valuation comparison: Anthropic $965B and OpenAI $852B
Most recent private-round valuations. Reminder: this is a private valuation, not IPO pricing.
ARR comparison: Anthropic $47B in May 2026 (official) and $65B in August (reported); OpenAI $25B in March and $40B in August (reported)
Two 2026 ARR points for each company. Figures are estimates; ARR is annualized, not full-year revenue actually received.

Expensive? Look at the valuation-to-revenue multiple

Same idea as judging a house by total price ÷ annual rent — higher multiple = pricier:

  • Anthropic: US$965B ÷ US$47B ≈ 20.5× [calculation]
  • OpenAI: US$852B ÷ US$25B ≈ 34× [calculation; ARR is a media figure]

Anthropic’s total valuation is higher, but its revenue is bigger too, so the price per dollar of revenue is actually lower. Using the reported US$65B ARR, the multiple drops to about 14.8×; using the reported US$2T IPO valuation, it rises to about 30.8×. These are rough frames, not trading signals.

The comparison with SpaceX is about transparency: SpaceX filed a public S-1 with full financials laid out; Anthropic and OpenAI both went confidential, with zero financial statements disclosed.

Valuation ÷ ARR: Anthropic about 20.5× on official ARR and 14.8× on August reported ARR; OpenAI about 34.1× on March and 21.3× on August reported ARR
A rough comparison using the same private valuation with ARR from different dates. Figures are estimates; ARR is annualized, not full-year revenue actually received.

Common Misreadings

Filing ≠ you can buy now: A confidential filing only secures an option. SEC review, a public formal S-1, a roadshow, and pricing all have to happen before shares trade.

Private valuation ≠ your purchase price: US$965 billion is a number negotiated by a few large institutions. IPO pricing comes after the roadshow, and it could be higher or lower.

ARR ≠ full-year actual revenue: A fast-growing company’s ARR is usually well above actual revenue. Remember US$47 billion (official) and US$65 billion (reported) — don’t force a growth multiple out of them.

Listing ≠ you can steer it: Anthropic is a public benefit corporation (PBC) whose charter lets directors balance shareholder interests against its AI-safety mission. It also has a Long-Term Benefit Trust (LTBT) — trustees with no financial stake in the company, holding special Class T shares with the power to elect and remove directors. LTBT-appointed directors already hold a board majority [filing]. Former Fed Chair Ben Bernanke has joined the LTBT [filing]. Buying this stock means accepting the premise: mission first, governance overseen by an independent trust.

Anthropic governance: LTBT holds Class T shares, controls board majority
Anthropic's PBC + trust governance. The independent trust controls a board majority; ordinary shareholders have economic interest but limited governance voice.

IPO Preparation Status

Since the confidential filing, Anthropic has been advancing on two tracks: compute expansion and listing preparation.

Compute Deals

Anthropic has no public financials, but deals with listed companies trigger mandatory SEC filings (8-Ks), so the numbers surface:

  • Broadcom: ~3.5 GW of next-gen TPU capacity from 2027 [counterparty 8-K]
  • SpaceX: access to the Colossus 1 supercomputer [media]
  • TeraWulf: 20-year lease, ~401 MW, ~US$19 billion, online H2 2027 [media + 8-K]
  • AMD: tens of billions in AI servers + up to US$5B investment, up to 2 GW of MI450 chips from 2027 [media]

Underwriting and Listing Prep

  • Underwriting led by Morgan Stanley and Goldman Sachs, with JPMorgan [media]
  • Investor-management meetings being arranged [media]
  • Company considering mandatory 10b5-1 trading plans for employees post-listing [media]
  • Reports say IPO valuation may exceed US$2 trillion; Q2 reportedly the first quarter of operating profit [media]
  • Listing timing rumored as early as October, but the company has never confirmed any date [media]

Export-Control Incident

In June, a U.S. export-control directive forced Anthropic to suspend Fable 5 and Mythos 5 for roughly three weeks before access was restored [filing]. A reminder: regulatory risk doesn’t disappear just because a company is preparing to list.

How to Participate by Region

No one can buy yet. Below is channel information for after listing, not a recommendation to buy.

General rule: IPO subscription (pre-listing allocations) and buying after listing are two different things. Allocations have high thresholds; retail investors almost never get them.

United States: The most direct. Ordinary secondary-market trading after listing. IPO allocations go to institutions first.

Taiwan: After listing, via sub-brokerage (domestic broker trading foreign securities) or overseas broker (e.g., IBKR). Watch for cross-border remittance and FX fees. U.S. stock income counts as overseas income under the Alternative Minimum Tax framework; check current-year rules.

Japan: Through brokers supporting U.S. stocks (SBI, Rakuten, Monex). Direct U.S. IPO subscription is uncommon; most buy after listing.

Mainland China: The hardest. QDII funds are the clearest compliant channel, with limited quota. The annual US$50,000 FX purchase quota generally cannot be declared for offshore securities investment.

Three Things to Remember

  • Separate the filing from the listing (a confidential filing is an option, not a commitment — no pricing, no listing, not buyable)
  • Separate the private valuation from the market price (US$965 billion is a private number; US$2 trillion is reported; IPO pricing comes at listing)
  • Separate the ARR from full-year actual revenue (US$47 billion and US$65 billion are annualized estimates, not receipts)

Until the formal S-1 is made public, every valuation and revenue number out there is still one layer removed. Waiting for the financials matters more than chasing a headline number.

To learn more about the company: What Is Anthropic?. To compare another tech IPO: How to Read the SpaceX IPO.

References

Figures are from official announcements and named media reports; final IPO terms will follow Anthropic’s official S-1 when made public.